Abstract
A randomized, double-blind, phase III study in India for comparing efficacy, safety, and PK of ZRC-3277 (pertuzumab biosimilar) with Perjeta® in patients with HER2-positive metastatic breast cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have